Blog
RSS FeedPosted by Michael Wonder on 05 Oct 2021
Pharmaceutical industry backs workplace vaccinations
5 October 2021 - Medicines Australia strongly recommends full COVID-19 vaccinations for the health and safety and protection of all ...
Posted by Michael Wonder on 21 Aug 2021
Competition, consolidation and evolution in the pharmacy market
12 August 2021 - Implications for efforts to contain drug prices and spending. ...
Posted by Michael Wonder on 14 Apr 2021
PhRMA's three part approach to build a better health care system
13 April 2021 - Our plan is based on three key pillars: ending the pandemic and building a more resilient system, ...
Posted by Michael Wonder on 21 Oct 2020
How the FDA stood up to the President
20 October 2020 - Dr. Stephen Hahn, the F.D.A. commissioner, occupies a fraught position, caught between pressure from the White House ...
Posted by Michael Wonder on 11 Jun 2020
Rare disease therapy development and access remain top FDA priorities during COVID-19
11 June 2020 - The FDA’s work on behalf of people with rare diseases is more important than ever as these ...
Posted by Michael Wonder on 16 Apr 2020
A strategy for improving U.S. health care delivery — conducting more randomised, controlled trials
16 April 2020 - Despite the prominence of randomised, controlled trials in medical research, they have rarely been used to evaluate ...
Posted by Michael Wonder on 08 Mar 2020
Five years on, biosimilars need support from all health care players
6 March 2020 - Today marks a milestone for the U.S. biosimilar market: the FDA approved our first biosimilar, Sandoz’s ...
Posted by Michael Wonder on 03 Mar 2020
The coronavirus could help pharma reset its reputation in Washington
3 March 2020 - The coronavirus outbreak could be the pharmaceutical industry’s ticket to saving its reputation in Washington. ...
Posted by Michael Wonder on 27 Nov 2019
Our drug policy often prioritises eliminating rare disease. One researcher asks: Is that the right goal?
26 November 2019 - Dr. Peter Bach wants to turn the entire philosophical underpinnings of America’s health care system upside ...
Posted by Michael Wonder on 21 Nov 2019
The challenges of sharing data in an era of politicised science
21 November 2019 - The goal of making science more transparent—sharing data, posting results on trial registries, use of preprint servers, ...
Posted by Michael Wonder on 15 Oct 2019
Wanted: better policies and incentives to revitalise R&D for new antimicrobial drugs
15 October 2019 - In the not-too-distant future that we could be facing — one with rampant, uncontrollable, multidrug-resistant microbes ...
Posted by Michael Wonder on 12 Sep 2019
Big Pharma is abusing patents, and it's hurting Americans
12 September 2019 - The American patent system has, since our nation's founding, served as a cornerstone of innovation. But ...
Posted by Michael Wonder on 11 Sep 2019
We need to make biosimilars easier to get
11 September 2019 - If potential biosimilar manufacturers can’t get their product to market, they won’t proceed with development. ...
Posted by Michael Wonder on 09 Sep 2019
FDA reiterates the importance of vaccines such as the Measles, Mumps, and Rubella (MMR) vaccine
6 September 2019 - The U.S. continues to experience cases and outbreaks of measles, largely due to unvaccinated or under-vaccinated segments ...
Posted by Michael Wonder on 02 Sep 2019
Biosimilars Forum’s public letter in response to anti-biosimilars Op-Ed
29 August 2019 - Government Should Not “Throw In the Towel on Biosimilars,” They Should Act Now to Unlock Billions ...